Compare CLDX to:
After Hours: 0.00 N/A (N/A) 7:00pm ET
| Last Trade: | 4.66 |
|---|---|
| Trade Time: | Jan 6 |
| Change: | 0.00 (0.00%) |
| Prev Close: | 4.66 |
| Open: | N/A |
| Bid: | N/A |
| Ask: | 4.94 x 500 |
| 1y Target Est: | 12.00 |
| Day's Range: | N/A - N/A |
|---|---|
| 52wk Range: | 4.16 - 14.19 |
| Volume: | 0 |
| Avg Vol (3m): | 346,472 |
| Market Cap: | 147.27M |
| P/E (ttm): | N/A |
| EPS (ttm): | -1.96 |
| Div & Yield: | N/A (N/A) |
| Thu, Dec 31 | CELLDEX THERAPEUTICS, INC. Files SEC form 8-K, Creation of a Direct Financial Obligation or an Obligation under an OfEDGAR Online |
| Mon, Dec 14 | [$$] Small-Caps Push Higherat The Wall Street Journal Online |
| Mon, Dec 14 | Early-Market Movers: XTO, Geronat Fox Business |
| Mon, Dec 14 | Clarient, Celldex: Early Volume Playsat TheStreet.com |
| Sun, Dec 13 | Celldex Therapeutics Presents Positive Results from Phase 2 Study of the Antibody-Drug Conjugate (ADC) Product Candidate CDX-011 in Advanced Breast CancerBusiness Wire |
| Mon, Dec 7 | Celldex Therapeutics to Present CDX-011 Clinical Data at the 32nd Annual CTRC-AACR San Antonio Breast Cancer SymposiumBusiness Wire |
| Wed, Nov 11 | CELLDEX THERAPEUTICS, INC. FinancialsEDGAR Online Financials |
| Fri, Nov 6 | CELLDEX THERAPEUTICS, INC. Files SEC form 10-Q, Quarterly ReportEDGAR Online |
| Thu, Nov 5 | Celldex Therapeutics to Present at Merriman Curhan Ford's Investor Summit 2009Business Wire |
| Thu, Nov 5 | New Star Analyst Rankings for Celldex Therapeutics, IncStarMine |
Quotes delayed, except where indicated otherwise.
Delay times are 15 mins for NASDAQ, NYSE and Amex.See also delay times for other exchanges.